

Pralatrexate, (S)-

Chemical Properties


CAS No. : 1320211-69-5

Formula: C₂₃H₂₃N₇O₅

Molecular Weight: 477.47

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Pralatrexate, (S)- is a folate analog dihydrofolate reductase (DHFR) inhibitor exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylation and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis.
Targets(IC50)	Others

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0944 mL	10.4719 mL	20.9437 mL
5 mM	0.4189 mL	2.0944 mL	4.1887 mL
10 mM	0.2094 mL	1.0472 mL	2.0944 mL
50 mM	0.0419 mL	0.2094 mL	0.4189 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

O'Connor OA, Amengual J, Colbourn D, Deng C, Sawas A. Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use. *Leuk Lymphoma*. 2017 Nov;58(11):2548-2557. doi: 10.1080/10428194.2017.1306642. Review. PubMed PMID: 28738754.

Makita S, Tobinai K. Mogamulizumab for the treatment of T-cell lymphoma. *Expert Opin Biol Ther*. 2017 Sep;17(9):1145-1153. doi: 10.1080/14712598.2017.1347634. Epub 2017 Jul 3. Review. Erratum in: *Expert Opin Biol Ther*. 2017 Sep;17(9):1183. PubMed PMID: 28649848.

Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemester FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. *Br J Haematol*. 2017 Mar;176(5):750-758. doi: 10.1111/bjh.14477. Epub 2016 Dec 16. PubMed PMID: 27983760; PubMed Central PMCID: PMC5836501.

Zinzani PL, Bonthapally V, Huebner D, Lutes R, Chi A, Pileri S. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas. *Crit Rev Oncol Hematol*. 2016 Mar;99:214-27. doi: 10.1016/j.critrevonc.2015.12.016. Epub 2016 Jan 3. Review. PubMed PMID: 26811013.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481